Nicox SA Achieves 100% Shareholder Approval at General Meetings and Announces Strategic Corporate Resolutions

Nicox SA, an international ophthalmology company listed on Euronext Growth Paris, conducted its Ordinary and Extraordinary General Meetings on May 6, 2024. Held at Sophia Antipolis, France, these meetings saw the adoption of all resolutions proposed by the Board of Directors, effectively achieving a quorum of 100% of eligible voting shares.

The General Meetings were overseen by SCP EZAVIN-THOMAS, represented by Maître Nathalie Thomas, appointed as the ad hoc agent by an order of the President of the Commercial Court of Antibes. This appointment followed the replacement of SELARL XAVIER HUERTAS & ASSOCIES, initially appointed on April 18, 2024, by a subsequent decision on April 25, 2024.

Key resolutions ratified during the meetings included the transfer of Nicox’s registered office to Sundesk Sophia Antipolis, Emerald Square, Rue Evariste Galois, 06410 Biot. Another significant resolution was the reduction of Nicox’s share capital from a nominal value of €1 per share to €0.01 per share, addressing the company’s financial losses.

Furthermore, the shareholders granted financial authorizations to the Board of Directors to undertake capital increases, both with and without preferential subscription rights. This flexibility aims to strengthen the company’s financial standing and strategic positioning in the market.

Another crucial resolution was the authorization for the Board to issue free shares and stock options to Nicox’s employees and corporate officers, enhancing the company’s ability to attract and retain top talent. Additionally, the agreement with BlackRock Inc., as disclosed on February 28, 2024, received shareholder approval. This agreement includes the appointment of Mrs. Sonia Benhamida and Mr. Maurizio Petitbon as observers, along with the authorization for the Board to issue bonds convertible into shares, providing further financial maneuverability.

Nicox SA focuses on developing innovative solutions to maintain and improve ocular health. Its lead clinical development program, NCX 470, is a novel nitric oxide-donating bimatoprost eye drop aimed at lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Besides its flagship project, Nicox generates revenue through VYZULTA® for glaucoma, exclusively licensed worldwide to Bausch + Lomb, and ZERVIATE® for allergic conjunctivitis, licensed in multiple regions, including the U.S. and Southeast Asia.

Headquartered in Sophia Antipolis, France, Nicox is part of the CAC Healthcare index and trades under the ticker symbol ALCOX on Euronext Growth Paris. The company remains committed to advancing its pipeline and collaborations to enhance ocular therapies globally.

Analyst coverage on Nicox includes Bryan, Garnier & Co, represented by Eric Yoo in Paris, and H.C. Wainwright & Co, represented by Yi Chen in New York. It is important to note that the views expressed in analyst reports do not reflect Nicox’s positions, and the company disclaims any obligation to update the information contained in these reports.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!